P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Scientists did a study with a special kind of cells called P-BCMA-ALLO1 allogeneic T stem cell memory CAR-T cells. They gave different doses to different groups of people with relapsed / refractory Multiple Myeloma. They wanted to see if the cells would work to treat the disease.
Scientists did a study with a special kind of cells called P-BCMA-ALLO1 allogeneic T stem cell memory CAR-T cells. They gave different doses to different groups of people with relapsed / refractory Multiple Myeloma. They wanted to see if the cells would work to treat the disease.
*Third Opinion AI Generated Synopsis
Trial Summary
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
![](https://thirdopinion.io/assets/misc_images/MMRF_Things_To_Consider-26b892a53958ded007db431255f18805f9bf1873a1c504a61569b9199867a0b7.png)